{"id":"sorafenib-sor","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Hand-foot skin reaction"},{"rate":"30-40%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Rash"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Hypertension"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Alopecia"},{"rate":"5-15%","effect":"Bleeding"}]},"_chembl":null,"_dailymed":{"setId":"b7919013-1511-44f0-a759-3fa78a9fa178","title":"SORAFENIB TOSYLATE (SORAFENIB) TABLET, FILM COATED [MYLAN PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sorafenib inhibits both intracellular (RAF/MEK/ERK) and receptor tyrosine kinases (VEGFR-2, VEGFR-3, PDGFR-β) that are critical for tumor growth and blood vessel formation. By targeting these pathways, it reduces tumor cell proliferation and impairs the tumor's ability to develop new blood vessels (angiogenesis), thereby limiting nutrient supply to cancer cells.","oneSentence":"Sorafenib is a multi-kinase inhibitor that blocks several protein kinases involved in tumor cell proliferation and angiogenesis, including RAF, VEGFR, and PDGFR.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:55:08.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"},{"name":"Renal cell carcinoma"},{"name":"Differentiated thyroid cancer (radioactive iodine-refractory)"}]},"trialDetails":[{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT03037437","phase":"PHASE2","title":"Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-02-16","conditions":"Hepatocellular Cancer","enrollment":64},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT03009461","phase":"PHASE2","title":"Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis","status":"COMPLETED","sponsor":"Peking University","startDate":"2017-06-01","conditions":"HepatoCellular Carcinoma, Portal Vein Thrombosis","enrollment":64},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT04599777","phase":"PHASE2","title":"TACE Combined With Sorafenib and Tislelizumab for Advanced HCC","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-10-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nexavar"],"phase":"marketed","status":"active","brandName":"Sorafenib (SOR)","genericName":"Sorafenib (SOR)","companyName":"The University of Texas Health Science Center at San Antonio","companyId":"the-university-of-texas-health-science-center-at-san-antonio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sorafenib is a multi-kinase inhibitor that blocks several protein kinases involved in tumor cell proliferation and angiogenesis, including RAF, VEGFR, and PDGFR. Used for Hepatocellular carcinoma, Renal cell carcinoma, Differentiated thyroid cancer (radioactive iodine-refractory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}